IBT Receives an STTR from NIAID for development of Bispecific Antibodies against multiple Ebolaviruses
A major challenge in the fight against filovirus infections is the fact that the nature of epidemics cannot be predicted. Beside the Zaire strain of Ebolavirus other ebolaviruses such as Sudan virus, Bundibugyo virus as well as the more distant relative Marburg virus have caused highly lethal outbreaks. One of the primary goals of IBT is to develop broadly protective antibodies against filoviruses.
Under this STTR, IBT will work with Dr. Jon Lai at the Albert Einstein College of Medicine (AECOM) to generate a series of novel bispecific antibodies that target multiple broadly neutralizing epitopes in filovirus glycoprotein. IBT and AECOM teams have already generated several prototypes that are currently under characterization. If successful, the antibodies will be transitioned into rodent and nonhuman primate studies under a Phase II STTR with the goal of development as a broadly protective immunotherapeutic for human use.